<DOC>
	<DOCNO>NCT01163903</DOCNO>
	<brief_summary>This single-centre , open label , dose finding , phase I study determine recommend phase II dose ( RP2D ) combination doxorubicin pantoprazole patient advance tumours standard treatment option . A minimum 3 patient enrol per dose level intra-patient dose escalation permit . Once RP2D identify , six additional patient metastatic solid tumour treat RP2D confirm tolerability .</brief_summary>
	<brief_title>Pantoprazole With Doxorubicin Advanced Cancer Patients With Extension Cohort Patients With Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<criteria>1 . Patients must histologically cytologically proven advanced solid tumour standard anticancer therapy exist 2 . Measureable nonmeasureable disease eligible , disease must evaluable defined RECIST 1.1 . 3 . Patients &gt; 18 year old 4 . At least 21 day since last chemotherapy regimen and/or radiotherapy 5 . Recovery reversible adverse event previous anticancer therapy baseline grade &lt; =1 , except alopecia . 6 . Patients must document evidence disease progression prior systemic therapy . 7 . ECOG Performance Status 0 1 8 . Adequate cardiovascular function history serious cardiac disease ( see Exclusion criterion definition ) Left ventricular ejection fraction &gt; 50 % multigated nuclear angiogram 9 . Patient consent must obtain accord Institutional REB requirement . The patient must sign consent form prior registration . 10 . Patients must accessible treatment followup . 11 . Previous Therapy 1 . Chemotherapy : Patients limited exposure prior anthracyclines define total dose 240 mg/m2 doxorubicin 300 mg/m2 epirubicin ( e.g . receive AC x 4 FEC x 3 adjuvant regimen ) . Patients prior exposure cardiotoxic anticancer drug ( e.g . mitoxantrone ) eligible . 2 . Radiation : Patients may prior radiation therapy ( include breast chest wall ) provide exceeded 25 % bone marrow reserve . 3 . Previous Surgery : Previous surgery permit provide wound heal occur . 4 . Hormonal Therapy : Patients may prior hormonal therapy . All hormonal agent must discontinue least 3 week prior study entry . 12 . Laboratory Requirements ( must do within 7 day prior registration ) 1 . Neutrophil count ( ANC ) &gt; = 1.5 x 10^9/L 2 . Hemoglobin &gt; = 90 g/L 3 . Platelet count &gt; = 100 x 10^9/L 4 . Bilirubin &lt; 1.5 x UNL 5 . AST ALT &lt; = 2 x UNL 6 . Creatinine &lt; = 1.5 x UNL creatinine clearance &gt; = 50mL/min 1 . Patients previously receive 240 mg/m2 doxorubicin 300 mg/m2 epirubicin . 2 . Patients receive concurrent treatment experimental drug anticancer therapy . 3 . Patients receive drug know interact pantoprazole , include : 1 . The antifungal agent fluconazole , itraconazole , ketoconazole , posaconazole , voriconazole ; 2 . The antiviral agent : atazanavir , delavirdine , indinavir , nelfinavir , raltegravir , saquinavir , tipranavir ; 3 . The anticoagulant agent : clopidogrel , dabigatran ; 4 . The immunosuppressive agent : mycophenolate 5 . The antiinflammatory agent : mesalamine 4 . Patients receive oral pantoprazole PPI inhibitor may participate agent discontinue least 7 day trial entry . 5 . Patients untreated brain meningeal metastasis . ( MR CT scan require rule unless clinical suspicion CNS disease ) . Patients treat stable brain metastasis eligible provide radiological evidence disease stabilization least 3 month duration asymptomatic . 6 . Patients history clinically significant cardiac disease , include : 1 . Unstable angina/ acute coronary syndrome 2 . Congestive heart failure 3 . Myocardial infarction within past year 4 . Clinically significant arrhythmia 5 . Pericarditis myocarditis 6 . Symptomatic valvular disease Patients wellcontrolled hypertension , uncomplicated mitral valve prolapse stable cardiac condition eligible . 7 . Patients active uncontrolled infection serious illness medical condition would permit patient manage accord protocol . 8 . Patients know bleed disorder . Patients stable anticoagulation warfarin s.c. heparin product eligible . Patients receive clopidogrel exclude . 9 . Patients unable unwilling give write , informed consent prior study participation . 10 . Women pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Advanced solid tumour</keyword>
	<keyword>Pantoprazole</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>PANTO IV</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>standard treatment option</keyword>
	<keyword>dose-escalation schedule</keyword>
	<keyword>Phase I</keyword>
	<keyword>single-centre</keyword>
	<keyword>open label</keyword>
	<keyword>dose find</keyword>
	<keyword>recommend phase II dose</keyword>
	<keyword>proton pump inhibitor</keyword>
	<keyword>advanced cancer</keyword>
	<keyword>anthracycline</keyword>
	<keyword>gastric acid secretion</keyword>
</DOC>